Mirum Pharmaceuticals マネジメント

マネジメント基準チェック /34

Mirum Pharmaceuticalsの CEO はChris Peetzで、 Mar2019年に任命され、の在任期間は 5.67年です。の年間総報酬は$ 6.45Mで、 10.2%給与と89.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.61%を直接所有しており、その価値は$ 12.12M 。経営陣と取締役会の平均在任期間はそれぞれ3.7年と4.3年です。

主要情報

Chris Peetz

最高経営責任者

US$6.5m

報酬総額

CEO給与比率	10.2%
CEO在任期間	5.7yrs
CEOの所有権	0.6%
経営陣の平均在職期間	3.7yrs
取締役会の平均在任期間	4.3yrs

経営陣の近況

Recent updates

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth

Jul 13

Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

May 28

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Apr 22

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mar 05

There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

Dec 26

What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Jun 10

Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Apr 18

Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU

Oct 14

Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth

Aug 17

Mirum Pharmaceuticals announces $80M stock offering

Aug 09

Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent

May 27

CEO報酬分析

Mirum Pharmaceuticals の収益と比較して、Chris Peetz の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$109m
Mar 31 2024	n/a	n/a	-US$159m
Dec 31 2023	US$6m	US$660k	-US$163m
Sep 30 2023	n/a	n/a	-US$164m
Jun 30 2023	n/a	n/a	-US$176m
Mar 31 2023	n/a	n/a	-US$129m
Dec 31 2022	US$4m	US$624k	-US$136m
Sep 30 2022	n/a	n/a	-US$42m
Jun 30 2022	n/a	n/a	-US$53m
Mar 31 2022	n/a	n/a	-US$70m
Dec 31 2021	US$4m	US$600k	-US$84m
Sep 30 2021	n/a	n/a	-US$179m
Jun 30 2021	n/a	n/a	-US$153m
Mar 31 2021	n/a	n/a	-US$132m
Dec 31 2020	US$3m	US$512k	-US$103m
Sep 30 2020	n/a	n/a	-US$84m
Jun 30 2020	n/a	n/a	-US$78m
Mar 31 2020	n/a	n/a	-US$68m
Dec 31 2019	US$6m	US$458k	-US$53m
Sep 30 2019	n/a	n/a	-US$61m
Dec 31 2018	US$385k	US$32k	-US$26m

報酬と市場: Chrisの総報酬 ($USD 6.45M ) は、 US市場 ($USD 5.27M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Chrisの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Chris Peetz (45 yo)

5.7yrs

在職期間

US$6,451,720

報酬

Mr. Christopher Peetz, also known as Chris, serves as Entrepreneur-in-Residence at Frazier Management, L.L.C since May 30, 2017. He also serves as Entrepreneur-in-Residence at Frazier Life Sciences Managem...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Christopher Peetz	CEO & Director	5.7yrs	US$6.45m	0.61% $ 12.1m
Peter Radovich	COO & President	4.6yrs	US$2.37m	0.042% $ 840.4k
Eric Bjerkholt	Chief Financial Officer	1.2yrs	US$4.69m	0.069% $ 1.4m
Pamela Vig	Chief Scientific Officer	less than a year	US$1.51m	0.19% $ 3.9m
Andrew McKibben	Vice President of Investor Relations and Finance	no data	データなし	データなし
Paul Ross	Chief Compliance Officer	4.6yrs	データなし	データなし
Erin Campany	Senior Vice President of Human Resources	5.8yrs	データなし	データなし
Lara Longpre	Chief Development Officer	5.9yrs	US$1.51m	0.20% $ 4.0m
Vinita Kumar	Senior vice President of Quality	2.8yrs	データなし	データなし
Jean-Luc Girardet	Senior Vice President of Technical Operations	1.8yrs	データなし	データなし
Joanne M. Quan	Chief Medical Officer	less than a year	データなし	データなし
Jolanda Howe	Senior VP & Global Controller	no data	データなし	0.0051% $ 102.0k

3.7yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: MIRMの経営陣は経験豊富であると考えられます ( 3.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Christopher Peetz	CEO & Director	no data	US$6.45m	0.61% $ 12.1m
Patrick Heron	Independent Director	6yrs	US$401.75k	0% $ 0
Laura Brege	Independent Director	5.3yrs	US$426.75k	0.021% $ 420.0k
Michael Grey	Independent Non-Executive Chairman of the Board	5.7yrs	US$451.75k	0.59% $ 11.8m
Laurent Fischer	Independent Director	5.4yrs	US$421.75k	0.014% $ 283.5k
Timothy Walbert	Independent Director	1.6yrs	US$671.53k	0% $ 0
Sona Saira Ramasastry	Independent Director	2.4yrs	US$411.75k	データなし
William Fairey	Independent Director	3.3yrs	US$411.75k	0% $ 0
Lon Cardon	Independent Director	2yrs	US$194.47k	0% $ 0

4.3yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: MIRMの取締役会は経験豊富であると考えられます ( 4.3年の平均在任期間)。

Mirum Pharmaceuticals マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Mirum Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

CEO & Director recently sold US$157k worth of stock

Mirum Pharmaceuticals, Inc. Announces Management Changes

Mirum Pharmaceuticals, Inc. Announces Management Appointments

Insider recently bought US$296k worth of stock

Mirum Pharmaceuticals, Inc. Appoints Eric Bjerkholt as the Chief Financial Officer

Recent updates

Mirum Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?

Mirum Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Volixibat in Treating Cholestatic Pruritus in PBC

Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish

Mirum Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Mirum Pharmaceuticals, Inc’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Olderer

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth

Mirum Pharmaceuticals, Inc.' LIVMARLI Approves in the European Union for Patients with PFIC

Mirum Pharmaceuticals Announces Positive Chmp Opinion for Livmarli® (Maralixibat) Oral Solution for the Treatment of Pfic in Patients Three Months of Age and Older

Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

Forecast breakeven date pushed back to 2026

Mirum Pharmaceuticals, Inc Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

Mirum Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Mirum Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada’S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome

Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mirum Pharmaceuticals, Inc. announced delayed annual 10-K filing

Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024

Mirum Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

CEO & Director recently sold US$157k worth of stock

Mirum Pharmaceuticals, Inc. Announces Management Changes

Mirum Pharmaceuticals, Inc. Announces Management Appointments

Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for Fourth Quarter 2023 and Full Year 2023

There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

Price target decreased by 12% to US$48.30

Mirum Pharmaceuticals, Inc. Announces Data from EMBARK Phase 2b Study for Biliary Atresia

Mirum Pharmaceuticals, Inc. Presents New Data at the Liver Meeting

Forecast breakeven date pushed back to 2025

Price target decreased by 7.2% to US$53.57

Mirum Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mirum Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Consensus estimates of losses per share improve by 22%

Mirum Pharmaceuticals, Inc. Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals, Inc. Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN

Mirum Pharmaceuticals, Inc. Announces Positive Phase 3 Restore Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis

Price target increased by 7.1% to US$59.20

Insider recently bought US$296k worth of stock

Mirum Pharmaceuticals, Inc. Appoints Eric Bjerkholt as the Chief Financial Officer

Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc. (NasdaqGM:TVTX).

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Mirum Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Mirum Pharmaceuticals's LIVMARLI Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome

Forecast breakeven date moved forward to 2024

Mirum Pharmaceuticals, Inc. announced that it expects to receive $210 million in funding from Frazier Life Sciences Management, LP, Avidity Partners Management, L.P., BVF Partners L.P., Longitude Capital Management Co., LLC, Sofinnova Investment, Inc. and another investor

President recently sold US$141k worth of stock

Mirum Pharmaceuticals, Inc. Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress

New major risk - Financial position

What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Mirum Pharmaceuticals, Inc. Announces Data from It's LIVMARLI Studies Presented at ESPGHAN Annual Meeting

Mirum Pharmaceuticals, Inc. Announces Hepatology Communications Publishes Data from CAMEO Study Evaluating Safety, Tolerability, and Efficacy of LIVMARLI® (Maralixibat) Oral Solution in Patients with Primary Sclerosing Cholangitis

Mirum Pharmaceuticals, Inc. Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study

No longer forecast to breakeven

Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Consensus revenue estimates increase by 16%

Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals, Inc. Announces Resignation of Ian Clements as Chief Financial Officer

Forecast to breakeven in 2025

Mirum Pharmaceuticals, Inc. Announces Resignation of Carol L. Brosgart, M.D. as A Director of the Company and as A Member of the Nominating and Corporate Governance Committee of the Board, Effective December 19, 2022

Mirum Pharmaceuticals, Inc. Appoints Lon Cardon to Board of Directors

Mirum Pharmaceuticals, Inc. Announces LIVMARLI (maralixibat) Approval by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older

Mirum Pharmaceuticals Provides Development Program Updates

Forecast to breakeven in 2024

Mirum Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Mirum Pharmaceuticals, Inc. Reports Positive Topline Data from Its Phase 3 March Study

Price target increased to US$56.63

マネジメント基準チェック /34